Drug

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
Academic conferenceCancer

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
JW Therapeutics' Carteyva Approved by Macau Health Bureau
Bristol-Myers SquibbCancer

JW Therapeutics’ Carteyva Approved by Macau Health Bureau

Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease
NASDAQ: SNYRare / orphan disease drugs

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease

Ascletis Pharma's Denifanstat Meets Phase III Endpoints in Severe Acne Trial
Ascletis PharmaClinical trial results

Ascletis Pharma’s Denifanstat Meets Phase III Endpoints in Severe Acne Trial

Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products
CamurusCVD

Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products

Show More